Tomoyuki Iwasaki1, Takaomi Kessoku2, Takuma Higurashi2, Masataka Taguri3, Masato Yoneda2. 1. Iwasaki Naika Clinic, 1-1-5-1F Kamihoshikawa, Hodogaya-ku, Yokohama, 240-0042 Japan. 2. 2Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan. 3. 3Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abstract
AIMS: The purpose of this study was to clarify the predictive clinical characteristics of therapy switching from sitagliptin to dulaglutide in patients with type 2 diabetes mellitus. METHODS: This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly. RESULTS: A total of 36 patients could be followed for 24 weeks of treatment with dulaglutide. They were assessed for several clinical parameters before the start of and 24 weeks after the study. Multiple linear regression analysis was used to search for independent predictors of reduction of hemoglobin A1c (HbA1c) levels after 24 weeks of treatment switching from sitagliptin to dulaglutide. Dulaglutide administration for 24 weeks resulted in significant reductions in fasting plasma glucose (FPG), HbA1c, and low-density lipoprotein cholesterol (LDL-C) levels. In addition, baseline HbA1c, FPG, body mass index (BMI), and age were significantly correlated with the change in HbA1c levels (ΔHbA1c). Furthermore, multiple linear regression analysis revealed that BMI and age significantly correlated with ΔHbA1c. CONCLUSION: In summary, our prospective 24-week study showed that baseline low BMI and old age are significantly useful in predicting the HbA1c-lowering effect of switching from sitagliptin to dulaglutide. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN000023245).
AIMS: The purpose of this study was to clarify the predictive clinical characteristics of therapy switching from sitagliptin to dulaglutide in patients with type 2 diabetes mellitus. METHODS: This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly. RESULTS: A total of 36 patients could be followed for 24 weeks of treatment with dulaglutide. They were assessed for several clinical parameters before the start of and 24 weeks after the study. Multiple linear regression analysis was used to search for independent predictors of reduction of hemoglobin A1c (HbA1c) levels after 24 weeks of treatment switching from sitagliptin to dulaglutide. Dulaglutide administration for 24 weeks resulted in significant reductions in fasting plasma glucose (FPG), HbA1c, and low-density lipoprotein cholesterol (LDL-C) levels. In addition, baseline HbA1c, FPG, body mass index (BMI), and age were significantly correlated with the change in HbA1c levels (ΔHbA1c). Furthermore, multiple linear regression analysis revealed that BMI and age significantly correlated with ΔHbA1c. CONCLUSION: In summary, our prospective 24-week study showed that baseline low BMI and old age are significantly useful in predicting the HbA1c-lowering effect of switching from sitagliptin to dulaglutide. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN000023245).
Authors: Z Skrivanek; B L Gaydos; J Y Chien; M J Geiger; M A Heathman; S Berry; J H Anderson; T Forst; Z Milicevic; D Berry Journal: Diabetes Obes Metab Date: 2014-05-22 Impact factor: 6.577
Authors: Carol Wysham; Thomas Blevins; Richard Arakaki; Gildred Colon; Pedro Garcia; Charles Atisso; Debra Kuhstoss; Mark Lakshmanan Journal: Diabetes Care Date: 2014-05-30 Impact factor: 19.112